161 related articles for article (PubMed ID: 7859019)
1. Management of hyperphosphatemia in patients with renal failure.
Ghazali A; Ben Hamida F; Bouzernidj M; el Esper N; Westeel PF; Fournier A
Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):566-79. PubMed ID: 7859019
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
[TBL] [Abstract][Full Text] [Related]
4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
5. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
Fournier A; Morinière P; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephrologie; 1995; 16(2):165-90. PubMed ID: 7753302
[TBL] [Abstract][Full Text] [Related]
6. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
7. Use of alkaline calcium salts as phosphate binder in uremic patients.
Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
[TBL] [Abstract][Full Text] [Related]
8. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
9. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
10. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
11. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
[TBL] [Abstract][Full Text] [Related]
12. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.
Delmez JA; Slatopolsky E
Am J Kidney Dis; 1992 Apr; 19(4):303-17. PubMed ID: 1562018
[TBL] [Abstract][Full Text] [Related]
13. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
[TBL] [Abstract][Full Text] [Related]
14. Phosphate binders for control of phosphate retention in chronic renal failure.
Loghman-Adham M
Pediatr Nephrol; 1999 Oct; 13(8):701-8. PubMed ID: 10502131
[TBL] [Abstract][Full Text] [Related]
15. Long-term suppression of hyperparathyroidism by phosphate binders in uremic children.
Tamanaha K; Mak RH; Rigden SP; Turner C; Start KM; Haycock GB; Chantler C
Pediatr Nephrol; 1987 Apr; 1(2):145-9. PubMed ID: 3153271
[TBL] [Abstract][Full Text] [Related]
16. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.
Locatelli F; Cannata-Andía JB; Drüeke TB; Hörl WH; Fouque D; Heimburger O; Ritz E
Nephrol Dial Transplant; 2002 May; 17(5):723-31. PubMed ID: 11981055
[TBL] [Abstract][Full Text] [Related]
17. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D.
Teruel JL; Nitvarro JF; Marcen R; Aguilera A; Tato A; Ottuño J
Miner Electrolyte Metab; 1997; 23(1):19-24. PubMed ID: 9058365
[TBL] [Abstract][Full Text] [Related]
18. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
19. Adynamic bone disease in patients with uremia.
Fournier A; Yverneau PH; Hué P; Said S; Hamdini N; Eldin HM; Mohageb S; Oprisiu R; Marie A; Solal ME
Curr Opin Nephrol Hypertens; 1994 Jul; 3(4):396-410. PubMed ID: 8076143
[TBL] [Abstract][Full Text] [Related]
20. High frequency of marked hyperphosphatemia during intravenous calcitriol therapy in hemodialysis patients with refractory hyperparathyroidism.
Descombes E; Vogel G; Rosman J; Wauters JP
Blood Purif; 1996; 14(3):234-41. PubMed ID: 8738537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
